Abstract: The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
March 7, 2023
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Jennifer Effie Amengual, Jennifer Lue, Owen A. O'Connor
Abstract: Provided are pharmaceutical compositions for skin lightening, which are particularly useful in treating skin hyperpigmentation, together with methods for their use. The compositions comprise glutathione conjugated to a peptide having a sequence comprising PKEK (SEQ ID NO: 1) and cysteamine or a pharmaceutical salt thereof.
Abstract: Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.
Type:
Grant
Filed:
September 21, 2020
Date of Patent:
February 28, 2023
Assignees:
UNIVERSITAT AUTONOMA DE BARCELONA, INSTITUT RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU, CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER BBN)
Inventors:
Antonio Pedro Villaverde Corrales, Esther Vazquez Gomez, Maria Virtudes Cespedes Navarro, Isolda Casanova Rigat, Neus Ferrer Miralles, Ramon Mangues Bafalluy, Ugutz Unzueta Elorza
Abstract: Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.
Type:
Grant
Filed:
November 1, 2018
Date of Patent:
February 28, 2023
Assignee:
The Regents of the University of California
Inventors:
Maurizio Pellecchia, Carlo Baggio, Luca Gambini, Parima Udompholkul
Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
February 28, 2023
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
Abstract: A fusion protein is provided, comprising i) a biologically active polypeptide; and ii) a half-life extending polypeptide moiety comprising 2-80 units independently selected the amino acid sequences according to SEQ ID NO: 1: X1-X2-X3-X4-X5-X6-D-X8-X9-X10-X11 (SEQ ID NO: 1) in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the biologically active polypeptide may thus be prolonged.
Type:
Grant
Filed:
April 16, 2018
Date of Patent:
February 21, 2023
Assignee:
Swedish Orphan Biovitrum AB (publ)
Inventors:
Joakim Nilsson, Erik Nordling, Stefan Svensson Gelius
Abstract: An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120° C. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.
Abstract: Disclosed are an amphiphysin-I mutant having anti-senescence activity and the use thereof. More particularly, disclosed are an amphiphysin-I mutant (AMPH-I) wherein valine (V), which is the 392nd amino acid in the amino acid sequence of amphiphysin-I (AMPH-I) represented by SEQ ID NO: 1, is substituted with glycine (G), a composition for suppressing aging and cellular senescence containing the amphiphysin-I mutant as an active ingredient, a pharmaceutical composition for preventing or treating senescence or a senescence-associated disease, a method for suppressing aging and cellular senescence, and a method for screening an inhibitor for aging and cellular senescence.
Type:
Grant
Filed:
March 24, 2021
Date of Patent:
February 14, 2023
Assignee:
Chungbuk National University Industrial-Academic Cooperation Foundation
Abstract: Provided are a surfactant adhesive protein comprising an amphiphilic peptide, as a surfactant adhesive protein, at the carbon or amine terminal, a silicone oil and an anticancer composition comprising the surfactant adhesive, where the surfactant adhesive enables homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of the mussel adhesive protein, and the surface adhesive can be favorably used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
February 14, 2023
Assignee:
TME THERAPEUTICS CO., LTD.
Inventors:
Sang Jae Lee, Bong Jin Hong, Min Chul Park
Abstract: Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and/or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
February 14, 2023
Assignees:
FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Abstract: Methods are described for increasing levels of healthy vaginal bacteria by treating the vaginal mucosa with bacteriocins derived from Lactobacillus paragasseri, Lactobacillus gasseri, and other bacterial strains. The bacteriocins are surprisingly advantageous as being selectively active against Lactobacillus iners but relatively inactive against H2O2-producing Lactobacillus species. Because L. iners is involved in the onset and maintenance of vaginal dysbiosis, selective removal of this bacterium from the vaginal microbiome treats or prevents conditions associated with vaginal dysbiosis, such as bacterial vaginosis and its sequelae.
Abstract: A micronutrient composition is highly effective in controlling high blood pressure while given to mammal for treating with or without prescribed pharmaceutical drug. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12 and calcium and magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure. The combined effects of the micronutrients contained in the micronutrient composition include increased production of NO “relaxing factor” and decreased activity of Angiotensin converting enzyme 1 (ACE1). ACE1 inhibitory effect of this natural formula was more pronounced than obtained with the pharmaceutical ACE1 inhibitor—Lisinopril—the commonly prescribed high blood pressure medication.
Abstract: Provided is a peptide having a short chain length, for example, having the number of amino acid residues of 20 or less and having a high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by Formula (1) in the specification and having the number of amino acid residues of 20 or less.
Type:
Grant
Filed:
August 8, 2017
Date of Patent:
January 31, 2023
Assignee:
TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES
Abstract: A peptide for regulating fat metabolism is described. The peptide is selected from the group consisting of: YLGASVPSPDPLEP (SEQ ID NO: 1); YLNNGLGAPAPYPDPLEP (SEQ ID NO: 4); PDPLEP (SEQ ID NO: 14); and PSPDPLEP (SEQ ID NO: 16).
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
January 31, 2023
Assignee:
SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY
Inventors:
Peigen Ren, Jian Zhang, Bin Teng, Jian Li, Zhenyu Yao
Abstract: The present invention relates to methods and compositions for modulating mannosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process, using a polyether ionophore.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
January 31, 2023
Assignee:
ARES TRADING S.A.
Inventors:
David Bruhlmann, Thomas Vuillemin, Martin Jordan, Hervé Broly
Abstract: Compositions and methods for combinatorial drug discovery in nanoliter droplets are described. Novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infection are disclosed.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
January 31, 2023
Assignees:
THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Paul Blainey, Anthony Kulesa, Jared Kehe
Abstract: Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.